You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

activated B cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Activated B-cell DLBCL (ABC DLBCL) Trial in United Kingdom, United States (Acalabrutinib)

Active, not recruiting
Has Results
  • Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
  • Los Angeles, California
  • +6 more
Dec 1, 2022

Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  • +8 more
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 8, 2023

Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type DLBCL (ABC-DLBCL), Mantle Cell Lymphoma (MCL) Trial in Indianapolis, Spokane

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • +4 more
  • Indianapolis, Indiana
  • +1 more
Jul 12, 2022

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting
  • B-ALL
  • +10 more
  • 131-I Apamistamab
  • CAR T-cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

Lymphoma, Lymphoma, B-Cell, Immune System Diseases Trial in Chapel Hill (iC9-CAR19 T cells, Bendamustine, Fludarabine)

Recruiting
  • Lymphoma
  • +4 more
  • iC9-CAR19 T cells
  • +4 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022

Pediatric Cancer, Hodgkin Disease, CD30-Positive DLBCL Trial in Milwaukee (anti-CD30 Bispecific Antibody-armed

Not yet recruiting
  • Pediatric Cancer
  • +11 more
  • anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)
  • Milwaukee, Wisconsin
    Children's Wisconsin
Sep 14, 2022

Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia Trial (Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi))

Not yet recruiting
  • Leukemia
  • +12 more
  • Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
  • (no location specified)
Mar 20, 2023

ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United

Active, not recruiting
  • ALK-Positive Large B-Cell Lymphoma
  • +34 more
  • Phoenix, Arizona
  • +32 more
Jan 3, 2023

Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T

Recruiting
  • Non-Hodgkin's Lymphoma
  • +2 more
  • CD19.CAR-CD28Z T Cells - dose escalation 2
  • CD19.CAR-CD28Z T Cells - dose escalation 1
  • Houston, Texas
  • +1 more
Feb 10, 2022

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Houston (autologous or syngeneic PBTLs and EBV-CTLs)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • autologous or syngeneic PBTLs and EBV-CTLs
  • Houston, Texas
  • +1 more
Feb 6, 2022

Ann Arbor Stage III DLBCL, Ann Arbor Stage IIX (Bulky) DLBCL, Ann Arbor Stage IV DLBCL Trial in United States (drug, other,

Suspended
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
  • +20 more
  • Tucson, Arizona
  • +110 more
Jan 31, 2023

Leukemia Trial (Donor Enriched Activated Natural Killer Cell Infusion)

Withdrawn
  • Leukemia
  • Donor Enriched Activated Natural Killer Cell Infusion
  • (no location specified)
Dec 20, 2022

DLBCL, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type Trial in Chicago (Cyclophosphamide, Doxorubicin

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Chicago, Illinois
    Northwestern University
Apr 30, 2021

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Hepatocellular Carcinoma Trial in Guangzhou (ADCC & TACE, TACE)

Completed
  • Hepatocellular Carcinoma
  • ADCC & TACE
  • TACE
  • Guangzhou, Guangdong, China
    The Third Affiliated Hospital of Sun Yat-sen University
Oct 28, 2020

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Hematopoietic Stem Cell Transplantation, Hematologic Malignancy Trial (CliniMACS®)

Not yet recruiting
  • Hematopoietic Stem Cell Transplantation
  • Hematologic Malignancy
  • CliniMACS®
  • (no location specified)
Oct 17, 2023

Glioblastoma Trial in Birmingham (Autologous genetically modified gamma-delta T cells, Allogeneic genetically modified

Not yet recruiting
  • Glioblastoma
  • Autologous genetically modified gamma-delta T cells
  • Allogeneic genetically modified gamma-delta T cells
  • Birmingham, Alabama
    University of Alabama at Birmingham
Dec 16, 2022

Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Salvador, Bahia, Brazil
    • +9 more
    Jul 24, 2023

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Phoenix (Autologous MUC1-activated T-cells,

    Recruiting
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Phoenix, Arizona
      Mayo Clinic Hospital in Arizona
    Jan 4, 2023

    B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • +2 more
    • CD19/CD22-bispecific CAR-T cells
    • Beijing, Beijing, China
      Liang Wang
    Oct 7, 2023

    Recurrent Glioblastoma Trial in Los Angeles (Activated T cells)

    Not yet recruiting
    • Recurrent Glioblastoma
    • Activated T cells
    • Los Angeles, California
      Cedars-Sinai Medical Center
    Apr 21, 2022

    Solid Tumor Trial in Yantai (DC-CIK combined with Chemotherapy, Chemotherapy)

    Recruiting
    • Solid Tumor
    • Yantai, Shandong, China
      Yantai Yuhuangding Hospital
    Feb 7, 2022

    Hemophilia B With Inhibitor, Hemophilia B Trial (SerpinPC)

    Not yet recruiting
    • Hemophilia B With Inhibitor
    • Hemophilia B
    • (no location specified)
    Mar 16, 2023

    Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia Trial in Philadelphia (CD3/CD28 Activated

    Terminated
    • Chronic Myelogenous Leukemia
    • +7 more
    • CD3/CD28 Activated T cells
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Aug 12, 2020